OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001348911

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. (CIK 0001348911, EIN 20-0915291) reported revenue of $50 million ($50,000,000) for FY2024 (2023-05-01 to 2024-04-30) and net income of -$183.44 million (-$183,444,000) for FY2025 (2024-05-01 to 2025-04-30), as filed in its 10-K filed 2025-07-10 (accession 0000950170-25-095011).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001348911
EIN20-0915291
SIC industry code2834 Pharmaceutical Preparations
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_5txdwy59f9g8nh2z6sewfwrrbw
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$50,000,000FY20242023-05-01 to 2024-04-3010-K2025-07-100000950170-25-095011Revenues
Net income-$183,444,000FY20252024-05-01 to 2025-04-3010-K2025-07-100000950170-25-095011NetIncomeLoss
Total assets$250,770,000FY2025as of 2025-04-3010-K2025-07-100000950170-25-095011Assets
Stockholders' equity$95,391,000FY2025as of 2025-04-3010-K2025-07-100000950170-25-095011StockholdersEquity
Operating cash flow-$152,907,000FY20252024-05-01 to 2025-04-3010-K2025-07-100000950170-25-095011NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$3.69 per shareFY20252024-05-01 to 2025-04-3010-K2025-07-100000950170-25-095011EarningsPerShareDiluted
Shares outstanding49,953,739 sharesFY2025as of 2025-06-2510-K2025-07-100000950170-25-095011EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20242023-05-01 to 2024-04-30$50,000,00010-K2025-07-100000950170-25-095011
RevenueFY20202019-05-01 to 2020-04-30$12,690,00010-K2022-07-070000950170-22-012521
RevenueFY20192018-05-01 to 2019-04-30$16,127,00010-K2021-07-130001564590-21-036441
RevenueFY20182017-05-01 to 2018-04-30$8,394,00010-K2018-07-300001564590-18-017915
RevenueFY20172016-05-01 to 2017-04-30$1,504,00010-K2018-07-300001564590-18-017915
Net incomeFY20252024-05-01 to 2025-04-30-$183,444,00010-K2025-07-100000950170-25-095011
Net incomeFY20242023-05-01 to 2024-04-30-$126,644,00010-K2025-07-100000950170-25-095011
Net incomeFY20232022-05-01 to 2023-04-30-$92,907,00010-K2024-07-110000950170-24-082965
Net incomeFY20222021-05-01 to 2022-04-30-$82,339,00010-K2024-07-110000950170-24-082965
Net incomeFY20212020-05-01 to 2021-04-30-$46,244,00010-K2023-07-100000950170-23-032298
Net incomeFY20202019-05-01 to 2020-04-30-$29,116,00010-K2022-07-070000950170-22-012521
Net incomeFY20192018-05-01 to 2019-04-30-$20,816,00010-K2021-07-130001564590-21-036441
Net incomeFY20182017-05-01 to 2018-04-30-$15,805,00010-K2020-07-010001564590-20-031501
Net incomeFY20172016-05-01 to 2017-04-30-$18,603,00010-K2019-07-160001564590-19-025009

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-05-142026-03-310001193125-26-223976kalv-20260331.htm
10-Q2025-11-102025-09-300001193125-25-274442kalv-20250930.htm
10-Q2025-09-112025-07-310001193125-25-200757kalv-20250731.htm
10-K2025-07-102025-04-300000950170-25-095011kalv-20250430.htm
10-Q2025-03-122025-01-310000950170-25-037995kalv-20250131.htm
10-Q2024-12-052024-10-310000950170-24-133673kalv-20241031.htm
10-Q2024-09-052024-07-310000950170-24-103981kalv-20240731.htm
10-K2024-07-112024-04-300000950170-24-082965kalv-20240430.htm
10-Q2024-03-112024-01-310000950170-24-029314kalv-20240131.htm
10-Q2023-12-072023-10-310000950170-23-068801kalv-20231031.htm
10-Q2023-09-072023-07-310000950170-23-047008kalv-20230731.htm
10-K2023-07-102023-04-300000950170-23-032298kalv-20230430.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001348911published by the sourcedata.sec.gov/submissions/CIK0001348911.json2026-10-21
Employer Identification Number (EIN) · US-EIN20-0915291published by the sourceaskebsa.dol.gov/FOIA%20Files/2024/Latest/F_5500_SF_2024_Latest.zip2026-10-22
Employer Identification Number (EIN) · US-EIN20-0915291published by the sourcedata.sec.gov/submissions/CIK0001348911.json2026-10-21

Same entity in other Olympus APIs

Records other Olympus APIs serve for this entity, linked through a published identifier (never matched on name).

APIRecordAPI pathLinked through
US Employee Benefits & Form 5500 APIsponsor/v1/form-5500/sponsors/200915291US-EIN 200915291

Former names

NameFromTo
Carbylan Therapeutics, Inc.2014-09-192016-11-21
Carbylan Biosurgery, Inc2013-01-032013-01-03
Carbylan Biosurgery Inc2005-12-292005-12-29

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001348911.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001348911.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001348911" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001348911/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001348911/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1348911"}

On SEC EDGAR

About this data